Impact of First-Line Sildenafil Monotreatment for Pulmonary Arterial Hypertension

Abstract

This study describes the long-term outcome of patients with PAH receiving sildenafil monotreatment as a first-line therapy and suggests that it is a promising therapeutic strategy.